News

Video

Dr Pellini on Comprehensive Genomic Profiling and Repeat Biomarker Testing in NSCLC

Related Videos
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Andrew Ip, MD
Anthony B. El-Khoueiry, MD
Daniel King, MD, PhD
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study